Inactive Instrument

News Benitec Biopharma Limited Deutsche Boerse AG

Equities

Summary

Unlock all the news: Be the first to know and act before the market!

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study	15/07	AQ
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study	15/07	CI
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors	01/07	AQ
Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors	01/07	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Index	01/07	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Index	01/07	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Index	01/07	CI
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell 3000E Value Index	01/07	CI
Piper Sandler Initiates Benitec Biopharma With Overweight Rating, $30 Price Target	13/06	MT
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	13/05	AQ
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	13/05	PU
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05	CI
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01/05	AQ
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	22/04	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Top Midday Gainers	19/04	MT
Top Premarket Gainers	18/04	MT
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04	AQ
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04	CI
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Benitec Biopharma Limited Deutsche Boerse AG

Equities

Summary

Filters